
Snowplow Unveils Signals: Real-Time Customer Intelligence Infrastructure for AI-Powered Products
BOSTON--(BUSINESS WIRE)--Snowplow, the leader in customer data infrastructure, today announced the launch of Snowplow Signals, a real-time customer intelligence system that enables companies to build and deploy AI-powered customer experiences much faster. Signals provides applications with access to deep, real-time, trustworthy customer context — making it easier to hyper-personalize user journeys and equip AI agents to overcome the 'cold start problem' and drive more relevant interactions.
'Signals transforms one-off customer interactions into deeply personalized, proactive experiences.' — Todd Boes, Chief Product Officer, Snowplow
Share
Long trusted by data teams at leading digital-first companies, Snowplow is now expanding its platform to support product, engineering, and data science teams building customer-facing AI-powered applications — such as personalization engines, adaptive UIs, and agentic applications like AI copilots and chatbots.
'By infusing real-time behavioral context into an application's memory, Signals transforms one-off customer interactions into deeply personalized, proactive experiences that drive measurable lift in customer engagement, conversion, and lifetime value,' said Todd Boes, Chief Product Officer at Snowplow. 'We're proud to partner with leading brands as they harness Signals to deliver the next generation of customer-intelligent applications.'
The Missing Link Between AI and Real-Time Customer Context
As organizations race to embed AI into their products, many hit a common set of roadblocks: they struggle to reliably identify who each user is in real-time, understand their current behavior, anticipate their needs, and serve deeply personalized experiences accordingly.
Existing data infrastructure often forces a trade-off — real-time speed without deep, trustworthy data, or deep, trustworthy data that is too slow to act on. Signals eliminates this compromise by providing extensible infrastructure for computing, retrieving, and acting on rich, well-governed customer data — both in-session and across historical context.
Snowplow Signals includes three core capabilities:
Profiles Store: Low-latency app and AI agent access to in-session and historical user attributes. The Profiles Store comes with two data processing engines to populate it:
Streaming Engine: Calculates real-time user attributes (e.g. in-session activity) from live event streams.
Batch Engine: Computes user attributes based on all of the historical customer data in your data warehouse or lakehouse (e.g. ML scores, lifecycle stage), including other customer data sets joined with behavioral data collected and processed by Snowplow.
Interventions: Engine for triggering real-time personalized actions based on real-time customer behavior (e.g. in-app nudges, dynamic offers or pricing, and proactive assistance from AI agents).
Fast-Start Tooling: Developer and data science tools to accelerate time-to-value, including Python and TypeScript SDKs for defining and retrieving user attributes and interventions, QuickStart guides, notebooks and code samples, and Solution Accelerators.
Built for Digital Product and Engineering Teams
Snowplow Signals is designed for teams building AI-powered products that want to deliver different experiences to different customers through the use of personalization and recommendation models and AI agents to drive revenue growth.
What sets Snowplow Signals apart:
Real-time personalization without compromise: Calculate and serve customer signals in-session with low latency — no trade-offs between speed and depth.
Declarative customer intelligence: Easily define user attributes declaratively (e.g. in Git) and access them seamlessly in your apps via SDKs.
Train once, deploy instantly: Use historical warehouse or lakehouse data to train ML features (i.e. customer attributes) and deploy them on live streaming data with no rework.
Model-agnostic: Integrate any LLM or ML model into your application logic— no black-box vendor systems.
Transparency and control: Run Signals in your cloud, with full governance, auditability, and data ownership.
'Snowplow Signals provides our product and engineering teams with the real-time customer intelligence infrastructure they need to build adaptive, AI-powered experiences into our FindMyPast product,' said Anup Purewal, Chief Data Officer at DC Thomson, a design partner for the release. 'With Signals, we can advance beyond static searches and singular actions to offer a genealogy experience that truly reflects the hobby — guiding each user's unique journey through our vast archives by proactively surfacing relevant content and suggesting next steps in real time. It's a game-changer for hyper-personalizing each user's deeply unique and personal experience.'
Deliver AI-Powered Experiences with Trusted Customer Data Infrastructure
Built on Snowplow's industry-leading real-time data pipeline and streaming engine, Signals ensures high-quality, consistent data across stream and warehouse — and delivers millisecond lookups with governance built in.
The new product offering runs natively in Snowplow customers' clouds and will support deployments on AWS, Azure, and GCP, with compatibility for Snowflake, Databricks, and BigQuery. Customers benefit from robust governance, built-in security, and full transparency across their end-to-end customer data operations.
Snowplow Signals marks a strategic expansion beyond data engineering to become foundational infrastructure for real-time, AI-driven digital experiences. As more companies move to productize AI, Signals positions Snowplow at the core of this transformation, unlocking new growth across product, engineering, and data science teams.
Availability
Snowplow Signals is currently available to select design partners, with general availability in Q3 2025. To learn more or request a custom demo, visit snowplow.io/signals.
Snowplow is the global leader in customer data infrastructure for AI, enabling every organization to transform raw behavioral data into governed, high-fidelity fuel for AI-powered applications — including advanced analytics, real-time personalization engines, and AI agents. Digital-first companies like Strava, HelloFresh, Auto Trader, Burberry, and DPG Media use Snowplow to collect and process event-level data in real time, delivering it securely to their warehouse, lake, or stream, and integrate deep customer context into their applications. Thousands of companies rely on Snowplow to uncover customer insights, predict customer behaviors, hyper-personalize customer experiences, and detect fraud in real time. Learn more: www.snowplow.io.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
7 hours ago
- Business Wire
Avistone Announces Encouraging Results for Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression at ASCO Annual Meeting 2025
BEIJING--(BUSINESS WIRE)--Beijing Avistone Biotechnology Co., Ltd ('Avistone'), an innovative biotechnology company focused on precision oncology therapeutics, today announced that the clinical data for Vebreltinib plus Andamertinib (PLB1004), its innovative combination of potent mesenchymal-epithelial transition factor (MET) inhibitor and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has been presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025. The details of the poster presentation are provided below: Poster title: Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression after failure on EGFR-TKIs treatment: phase Ib/II KYLIN-1 study Abstract Number For Publication: 8632 Session: Poster Session-Lung Cancer- Non-Small Cell Metastatic Location: Poster Board, 112 Session Date/Time: 5/31/2025 1:30pm-4:30pm CDT MET amplification or overexpression is the most common 'off-target' mechanism that drives resistance to EGFR-TKIs in NSCLC patients. The results from Phase Ib/II KYLIN-1 study (NCT06343064) showed that Vebreltinib plus Andamertinib demonstrated notable efficacy and manageable safety in EGFR-mutated NSCLC patients with MET amplification or overexpression after EGFR-TKIs failure. Among the 56 patients enrolled at a dose of Vebreltinib 150mg BID plus Andamertinib 80mg QD (RP2D), the confirmed overall response rate (ORR) was 50.0%, and the median progression-free survival (mPFS) was 9.9 months. In 19 patients with brain metastases, ORR was 42.1% and mPFS was 9.5 months. Grade 3 or higher treatment related adverse events (TRAEs) occurred in 19.6% of the patients. None discontinued treatment or died due to TRAEs. No new safety signal was observed. A multicenter Phase III study, KYLIN-3 study (NCT06970782), is currently ongoing to further evaluate Vebreltinib plus Andamertinib versus platinum-based doublet chemotherapy in patients with EGFR mutations, MET amplification and/or overexpression, locally advanced or metastatic NSCLC following EGFR-TKI failure. To obtain a copy of the poster, please email Avistone. About Vebreltinib Vebreltinib is an orally, potent and selective c-Met inhibitor. Chinese National Medical Products Administration (NMPA) has formally approved the use of Vebreltinib in locally advanced or metastatic NSCLC patients with MET exon 14 skipping mutations, as well as adult patients with isocitrate dehydrogenase mutant astrocytoma with the PTPRZ1-MET fusion gene or glioblastoma with a history of low-grade disease who have the PTPRZ1-MET fusion gene and have failed previous treatments. Currently, Chinese Center for Drug Evaluation (CDE) has formally accepted its New Drug Application (NDA) and granted it priority review, intended for patients with locally advanced or metastatic NSCLC with MET amplification. About Andamertinib (PLB1004) Andamertinib (PLB1004) is an oral, potent, irreversible, and selective EGFR-TKI with potent blood-brain barrier penetration and broad tyrosine kinase activity. Preclinical studies have shown that it can effectively and irreversibly target exon 20 insertion. Additionally, it can also potently target classical EGFR mutations, such as Del19, L858R and T790M with a high degree of selectivity. About Avistone Biotechnology Beijing Avistone Biotechnology Co., Ltd. ('Avistone') is an innovative biotechnology company dedicated to precision therapies with significant unmet medical needs for patients worldwide. Avistone maintains an extensive pipeline of targeted therapies in Non-Small Cell Lung Cancer (NSCLC) and other solid tumors.


Business Wire
9 hours ago
- Business Wire
BIOSIG TECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of BioSig Technologies, Inc.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed merger of BioSig Technologies, Inc. (NasdaqCM: BSGM) and Streamex Exchange Corporation. Upon closing of the proposed transaction, current BioSig shareholders and holders of common stock equivalents will hold 25% of the fully diluted BioSig common stock outstanding. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to BioSig shareholders. If you would like to discuss your legal rights regarding the proposed transaction, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit


Business Wire
10 hours ago
- Business Wire
SIGNING DAY SPORTS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Signing Day Sports, Inc.
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed merger of Signing Day Sports, Inc. (NYSE: SGN) and One Blockchain LLC. Upon closing of the proposed transaction, Signing Day shareholders are expected to own approximately 8.5% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to Signing Day shareholders. If you would like to discuss your legal rights regarding the proposed transaction, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit